Prolactin and antipsychotic medications: Mechanism of action

Schizophrenia Research

Volumn 35, Issue SUPPL., 1999, Pages

  Petty, Richard G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antipsychotic agents; Dopamine; Hyperprolactinemia; Prolactin; Sexual dysfunction

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE;

AMENORRHEA; CONFERENCE PAPER; DRUG MECHANISM; HIRSUTISM; HUMAN; HYPERPROLACTINEMIA; LACTATION; OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION;

AMENORRHEA; ANTIPSYCHOTIC AGENTS; CIRCADIAN RHYTHM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PROLACTIN; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 0033105858     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00158-3     Document Type: Conference Paper

References (38)

1. Allen D.L., Mitchner N.A., Uveges T.E., Nephew K.P., Khan S., Ben-Jonathan N. Cell-specific induction of c-fos expression in the pituitary gland by estrogen. Endocrinology. 138:1997;2128-2135.
2. Arita J., Kimura F. Characterization of in vitro dopamine synthesis in the median eminence of rats with haloperidol-induced hyperprolactinemia and bromocriptine-induced hypoprolactinemia. Endocrinology. 119:1986;1666-1672.
3. Arita J., Kimura F. Direct inhibitory effect of long-term estradiol treatment on dopamine synthesis in tuberoinfundibular dopaminergic neurons: in vitro studies using hypothalamic slices. Endocrinology. 121:1987;692-698.
4. Asnis G.M., Sachar E.J., Halbreich U., Ostrow L.C., Nathan R.S., Halpern F.S. The prolactin-stimulating potency of reserpine in man. Psychiatry Res. 5:1981;39-45.
5. Baron J.C., Martinot J.L., Cambon H.et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology. 99:1989;463-472.
6. Beasley C.M. Jr., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124:1996;159-167.
7. Belchetz P.E., Ridley R.M., Baker H.F. Studies on the accessibility of prolactin and growth hormone to brain: effect of opiate agonists on hormone levels in serial, simultaneous plasma and cerebrospinal fluid samples in the rhesus monkey. Brain Res. 239:1982;310-314.
8. Bohnet H.G., Dahlen H.G., Wuttke W., Schneider H.P.G. Hyperprolactinemic anovulatory syndrome. J. Clin. Endocrinol. Metab. 42:1976;132-143.
9. Borison R.L., Arvanitis L.A., Miller B.G. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US Seroquel Study Group. J. Clin. Psychopharmacol. 16:1996;158-169.
10. Bowden C.R., Voina S.J., Woestenborghs R., De Coster R., Heykants J. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J. Pharmacol. Exp. Ther. 262:1992;699-706.
11. Brown W.A., Laughren T.P. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res. 5:1981;317-322.
12. Brown W.A., Laughren T.P., Williams B. Differential effects of neuroleptic agents on the pituitary-gonadal axis in men. Arch. Gen. Psychiatry. 38:1981;1270-1272.
13. Bunker M.T., Marken P.A., Schneiderhan M.E., Ruehter V.L. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J. Child Adolesc. Psychoparmacol. 7:1997;65-69.
14. Chouinard G., Annable L., Jones B.D., Collu R. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatr. Scand. 64:1981;353-362.
15. Clemens J.A., Smalstig E.B., Sawyer B.D. Antipsychotic drugs stimulate prolactin release. Psychopharmacology. 40:1974;123-127.
16. Cohn J.B., Brust J., DiSerio F., Singer J. Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology. 13:1985;173-179.
17. Curtis V.A., Wright P., Reveley A., Kerwin R., Lucey J.V. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry. 166:1995;642-646.
18. Ghadirian A.M., Chouinard G., Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 170:1982;463-467.
19. Gold M.S., Redmond D.E., Donabedian R.K., Goodwin F.K., Extein I. Increase in serum prolactin by exogenous and endogenous opiates: evidence for antidopamine and antipsychotic effects. Am. J. Psychiatry. 135:1978;1415-1416.
20. Green A.I., Brown W.A. Prolactin and neuroleptic drugs. Endocrinol. Metab. Clin. North Am. 17:1988;213-223.
21. Gregerson K.A., Selmanoff M. Selective effects of hyperprolactinemia on in vitro dopamine release from median eminence synaptosomes. J. Neurosci. 8:1988;2477-2484.
22. Gunnet J.W., Moore K.E. Neuroleptics and neuroendocrine function. Annu. Rev. Pharmacol. Toxicol. 28:1988;347-366.
23. Hamner M.B., Arvanitis L.A., Miller B.G., Link C.G., Hong W.W. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol. Bull. 32:1996;107-110.
24. Huang M.L., Van Peer A., Woestenborghs R.et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54:1993;257-268.
25. Kane J.M., Cooper T.B., Sachar E.J., Halpern F.S., Bailine S. Clozapine: plasma levels and prolactin response. Psychopharmacology. 73:1981;184-187.
26. 2 receptor-deficient mice. Neuron. 19:1997;103-113.
27. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 124:1996;2-34.
28. Lamberts S.W., van Koetsveld P.M., Hofland L.J. The effect of clozapine on prolactin secretion at the level of the lactotroph. Life Sci. 46:1990;1013-1019.
29. Lerer B., Ran A., Blacker M.et al. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction. Schizophr. Res. 1:1988;405-410.
30. MacLeod R.M., Robyn C. Mechanism of increased prolactin secretion by sulpiride. J. Endocrinol. 72:1977;273-277.
31. Pontiroli A.E., Baio G., Stella L.et al. Effects of naloxone on prolactin, luteinizing hormone and cortisol responses to surgical stress in humans. J. Clin. Endocrinol. Metab. 55:1982;378-380.
32. Ramos J.A., Pais J.R., Cebeira M., Fernandez-Ruiz J. Role of estrogens on striatal dopaminergic activity. J. Steroid Biochem. Mol. Biol. 27:1987;683-689.
33. Rolland R., Corbey R.S. Hyperprolactinemia and hypogonadism in the human female. Eur. J. Obstet. Gynecol. Reprod. Biol. 7:1977;337-348.
34. Selmanoff M. The lateral and medial median eminence: distribution of dopamine, norepinephrine, and luteinizing hormone-releasing hormone and the effect of prolactin on catecholamine turnover. Endocrinology. 108:1981;1716-1722.
35. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry. 54:1997;549-557.
36. Tollefson G.D., Beasley C.M. Jr., Tran P.V.et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
37. Tran P.V.et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17:1997;407-418.
38. Veldhuis J.D., Evans W.S., Stumpf P.G. Mechanisms that subserve estradiol's induction of increased prolactin concentrations: evidence of amplitude modulation of spontaneous prolactin secretory bursts. Am. J. Obstet. Gynecol. 161:1989;1149-1158.